Paclitaxel in treating non-small cell lung cancer: A systematic review

Abstract

Abstract: AIM: To assess the clinical efficacy and safety of paclitaxel in treating non-small cell lung cancer.METHODS: The Wanfang database was searched. The randomized control studies on paclitaxel treating non-small cell lung cancer were brought into the research.RESULTS: A total of 25 randomized control studies with 2160 cases of small cell lung cancer were brought into the research.The Meta analysis showed that the response rate of taxol treatment prescription was higher than that of control group[O R=1.12, 95 %CI(1.03, 1.23)] ;The incidence rate of leukopenia at grade Ⅲ and above was higher [OR =1.35, 95 %CI (1.05, 1.74)] than that of control group ;The incidence rate of induced thrombocytopenia at degree Ⅲ and above was decreased compared with control group [O R=0.37, 95 %CI(0.24, 0.58)] ;The incidence rate of induced digestive tract react ions at degre ; There were no significant differences of 1-year survival between treatment group and control group after chemotherapy [O R =1.15, 95 %CI (0.94, 1.40)].CONCLUSION: There is a certain therapeutic effect of paclitaxel in treating non-small cell lung cancer.Since there is a possible existence of bias in this systematic review of research, the results will affect the strength of the argument and more high-quality randomized double-blind controltrials were look forward.

Key words: Non-small cell lung cancer, Paclitaxel, Metaanalysis, Randomized cont rolled trial, Systematic review

CLC Number:

R969.4

LI Yan-hong, ZHU Huai-jun. Paclitaxel in treating non-small cell lung cancer: A systematic review[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 74-81.

References

[1] 肺癌已经成为累计危险性最高的癌症[EB/ OL]. http://news. csco. net. cn/class/detail. asp?u =288.
[2] Rivera MP. Multimodality therapy in the treatment of lung cancer [J]. Semin Respir Crit Care Med, 2004, 25(Suppl 1): 3-10.
[3] 国家食品药品监督管理局药品审评中心, 四川美康医药软件研究开发有限公司, 主编. 药物临床信息参考[M]. 成都:四川科学技术出版社, 2004: 324-325.
[4] 杭达明, 谢国栋, 张葆春. GP 方案与TP 方案一线治疗晚期非小细胞肺癌的临床观察[J]. 临床肿瘤学杂志, 2008, 13(2): 133-136.
[5] 黄福喜, 曹小龙. GP 方案与TP 方案治疗晚期非小细胞肺癌的比较[J]. 中国现代医生, 2008, 46(34): 13-14.
[6] 勾红峰, 陈心传, 侯梅, 等. GP 和TP 方案治疗晚期非小细胞肺癌的随机对照临床研究[J]. 中国肺癌杂志, 2007, 10(2): 141-143.
[7] 陈鹏, 熊海林, 李丽庆, 等. GP 与TP 方案治疗晚期非小细胞肺癌随机对照研究[J]. 天津医科大学学报, 2006, 12(2): 246-249.
[8] 李新权. NP 方案和TP 方案治疗晚期非小细胞肺癌的临床观察[J]. 中国医药导报, 2009, 6(11): 29-30.
[9] 侯恩存, 张海燕. NP 方案与TP 方案治疗晚期非小细胞肺癌的临床研究[J]. 重庆医学, 2009, 38(3): 323-324.
[10] 田伶伶. TP 方案与NP 方案治疗晚期非小细胞肺癌的临床疗效分析[J]. 中国现代医生, 2008, 46(11): 150.
[11] 杨卫卫, 康婷, 杜延玲. TP 方案与NP 方案治疗晚期复发性非小细胞肺癌的临床疗效比较[J]. 延安大学学报:医学科学版, 2007, 5(3): 10-11.
[12] 潘荣强, 李光明, 文世民. TP 与EP 方案治疗晚期非小细胞肺癌的临床对比观察[J]. 川北医学院学报,2005, 20(2): 130-132.
[13] 马英. TP 与NP 方案治疗晚期非小细胞肺癌比较观察[J]. 中外医疗, 2008, 29:65.
[14] 安煜致, 王新华, 张欣. TP 与NP 方案治疗晚期非小细胞肺癌的比较观察[J]. 中华肿瘤防治杂志, 2007,14(5): 399.
[15] 赵亚超, 朱长亮, 张志培, 等. 铂类为基础的三种化疗方案治疗晚期非小细胞肺癌的临床研究[J]. 现代肿瘤医学, 2008, 16(3): 375-377.
[16] 尹先哲, 蔡芳. 不同化疗方案联合放疗治疗Ⅲ 期非小细胞肺癌[J]. 实用诊断与治疗杂志, 2007, 21(6): 415-416.
[17] 郭守俊, 曾红学, 康昭沟, 等. 长春瑞滨联合顺铂与紫杉醇联合顺铂方案治疗晚期非小细胞肺癌的疗效比较[J]. 赣南医学院学报, 2006, 26(4): 507-509.
[18] 蔡勇, 张珊文, 尹先哲, 等. 放射治疗同时化疗Ⅲ 期非小细胞肺癌[J]. 中华放射肿瘤学杂志, 2001, 10(1): 31-33.
[19] 官成浓, 潘达超, 张英, 等. 国产紫杉醇联合方案对60 岁以上晚期非小细胞肺癌患者近期生存质量的影响[J]. 肿瘤防治研究, 2005, 32(9): 571-573.
[20] 刘联, 王秀问, 黎莉, 张听, 张文东, 于学军含顺铂的三组联合化疗方案治疗晚期非小细胞肺癌的随机对照临床研究[J] 癌症, 2006, 25(8): 990-994.
[21] 江涛, 熊慧群, 唐小葵, 等. 吉西他滨加卡铂与紫杉醇加卡铂治疗晚期非小细胞肺癌临床对比研究[J]. 中国肺癌杂志, 2003, 2: 89-91.
[22] 郑瑾, 白桦, 叶建增, 等. 吉西他滨与紫杉醇联合顺铂两方案治疗晚期非小细胞肺癌的临床对比观察[J]. 临床肿瘤学杂志, 2003, 8(4): 263-265.
[23] 王玫玫, 边吉来. 吉西他滨与紫杉醇治疗老年晚期非小细胞肺癌疗效比较[J]. 中国医药导报, 2008, 5(21): 73-74.
[24] 崔同建, 刘振华, 陈峥, 等. 晚期非小细胞肺癌4 种化疗方案临床对照研究[J]. 肿瘤学杂志, 2006, 12(2): 136-138.
[25] 江波, 赵金奇, 涂长玲, 等. 晚期非小细胞肺癌不同化疗方案的疗效比较[J]. 实用癌症杂志, 2008, 23(2): 161-163.
[26] 王润莲, 杨学峰, 张敏, 等. 紫杉醇和诺维苯治疗晚期非小细胞肺癌疗效比较[J].
[27] 肖宝荣, 朱兆峰, 贾惠, 等. 紫杉醇联合适形放疗治疗局部晚期非小细胞肺癌的疗效观察[J]. 中国医院药学杂志, 2005, 25(11): 1056-1057.
[28] 贾筠, 莫汉文, 成奇峰, 等. 紫杉醇与吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床观察[J].
[28] 贾筠, 莫汉文, 成奇峰, 等. 紫杉醇与吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床观察[J]. 华西医学, 2005, 20(3): 496-498.
[29] 靳颖华, 张卫东, 齐平. 痰热清注射液治疗支气管炎的Meta 分析[J].
[29] 靳颖华, 张卫东, 齐平. 痰热清注射液治疗支气管炎的Meta 分析[J]. 首都医药, 2008, 12: 30-31.
[30] 杨佳丹, 欧阳净. 文拉法辛与氟西汀治疗抑郁症疗效比较的Meta 分析[J]. 中国神经精神疾病杂志,2009, 35(1): 30-34.
[31] 国家食品药品监督管理局药品审评中心, 四川美康医药软件研究开发有限公司, 主编. 药物临床信息参考[M]. 成都:四川科学技术出版社, 2004: 324-325.
[32] 郑积华. 150 例老年晚期非小细胞肺癌不同治疗方案回顾性分析[J]. 中国肺癌杂志, 2009, 12(2): 122-126.
[33] Smit EF, Van Meerbeck JP, Lianes P, et al. Threearm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975[J]. J Clin Oncol, 2003, 21(21): 3909-3917.
[34] Langer CJ, Manola J, Bernar do P, et al. Cisplatinbased therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial[J]. J Natl Cancer Inst, 2002, 94(3): 173-181.
[35] Mark A, Socinski A, wmiam B, et al. Randomized phase IItrial of induction chemo therapy followed by concurrent chemotherapy and do se-escalated thoracic conformal radiotherapy (74Gy) in stage III nonsmall-cell lung cancer: CALGB 30105[J]. J Clin Onco l, 2008, 26(15): 2457-2463.